BofA上调Hims and Hers目标价，因FDA药品更新
BofA Securities调整了对Hims and Hers (NYSE:HIMS)的展望，将目标价从20.00美元上调至23.00美元，并维持买入评级。这一调整是基于美国食品和药物管理局（FDA）最近宣布重新评估曾列入短缺清单的tirzepatide药物的可用性。 FDA在周五的一份法庭文件中表示，将重新考虑早前将tirzepatide从短缺清单中移除的决定。该机构还指出，在审查该活性成分的 ...
证券之星2 小时
FDA“三思“将礼来(LLY.US)减肥神药移除短缺名单，Hims & Hers Health(HIMS.US ...
智通财经APP获悉，在美国食品药品监督管理局 (FDA)决定将礼来公司 (LLY.US)的替西帕肽 (Tirzepatide)从药品短缺清单中移除后，一起针对此次除名举措的诉讼引发了Hims & Hers Health (HIMS.US)周一交易上涨，收涨9.68%。这场诉讼导致FDA现正对除名重新考虑。替西帕肽以Mounjaro和Zepbound的名称出售，分别用于治疗2型糖尿病和减肥症。
Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage
The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...
FiercePharma13 小时
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on ...
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
FDA Reversal on Knockoff GLP-1 Drugs Brings Confusion, and Few Answers
A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...
FDA To Reassess Ban On Cheaper, Compounded Versions of Eli Lilly Weight Loss Drugs
The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...
Becker's Hospital Review12 小时
FDA to reconsider decision barring sale of compounded Mounjaro: 5 things to know
The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.
美国肥胖群体的福音：FDA考虑允许复配版礼来减肥药
该机构在一份法庭文件中表示，现在将考虑允许复配药房和药物基础设施继续提供相应的药物，同时表示重新审查其活性成分是否短缺。对于肥胖以及糖尿病群体来说，礼来兼具减肥以及降糖功能的药物的复合配制版本比礼来的官方品牌版本更便宜。
STAT3 天
In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list
The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...
Truist维持对HIMS的持有评级，FDA审查进展引关注
Truist Securities维持对Hims & Hers Health, Inc. (NYSE:HIMS)的持有评级，目标价保持在$23.00。该公司分析师引用了美国食品和药物管理局(FDA)最近决定重新审视Tirzepatide短缺问题，并继续授权复合药房生产其复合版本，认为这对公司前景有利。 这一决定对Hims & Hers的复合GLP-1产品尤为相关，该产品使用的Semaglutide ...
US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...
FDA将礼来GLP-1减肥药从短缺名单中删除，配药团体提起诉讼
美国 FDA 于上周宣布胰高血糖素样肽1（GLP-1）药物替尔泊肽（tirzepatide）注射液的短缺问题已得到解决，并提醒配药商配制已获得 FDA 批准的药品受到法律限制。根据配药相关法律规定，如果已批准的药品在 FDA ...